# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Idiopathic pulmonary fibrosis

Familial pulmonary fibrosis
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 81-90 of 364 results.
68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis
Status: Terminated
Last Changed: Jan 27, 2015
First Received: Mar 24, 2011
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): 68Ga-DOTA-NOC PET/CT
Locations: Nuclear Medicine, Azienda Ospedaliero Universitaria di Bologna, Policlinico S.Orsola Malpighi, Bologna, Italy
A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: Aug 25, 2020
First Received: Sep 16, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): PRM-151, placebo
Locations: UCSF Interstitial Lung Disease Program, San Francisco, California, United States
National Jewish Medical and Research Center, Denver, Colorado, United States
Yale University School of Medicine, New Haven, Connecticut, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
University of Louisville Hospital, Louisville, Kentucky, United States
... and 14 other locations.
Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis
Status: Completed
Last Changed: Nov 09, 2017
First Received: Aug 21, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): 4 metre gait speed
Locations: Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom
Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Status: Completed
Last Changed: Mar 06, 2020
First Received: Jun 02, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Cyclophosphamide, Placebo, Corticosteroid (prednisolone)
Locations: Hôpital Tenon, Paris, France
This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.
Status: Completed
Last Changed: Oct 24, 2019
First Received: Feb 05, 2018
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): BI 1015550, Placebo
Locations: Brussels - UNIV Saint-Luc, Bruxelles, Belgium
Odense University Hospital, Odense, Denmark
HYKS Keuhkosairauksien tutkimusyksikkö, Helsinki, Finland
TYKS, Keuhkosairauksien klinikka, Turku, Turku, Finland
Fraunhofer ITEM, Hannover, Germany
... and 9 other locations.
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis
Status: Recruiting
Last Changed: Jul 14, 2020
First Received: May 06, 2019
Disease(s): Progressive Idiopathic Pulmonary Fibrosis
Intervention(s): pirfenidone and nintedanib, pirfenidone or nintedanib
Locations: Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France
Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study
Status: Unknown status
Last Changed: Sep 11, 2006
First Received: Sep 20, 2005
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): minocycline
Locations: UCLA Pulmonary Outpatient Clinic, Los Angeles, California, United States
PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
Status: Active, not recruiting
Last Changed: Aug 31, 2020
First Received: Apr 03, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Locations: Johns Hopkins University, Baltimore, Maryland, United States
Jody McCullough, Hershey, Pennsylvania, United States
Anuradha Paranjape, Philadelphia, Pennsylvania, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
University of Utah, Salt Lake City, Utah, United States
... and 1 other locations.
A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: May 20, 2016
First Received: Mar 14, 2016
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Matching Placebo, N-acetylcysteine, Pirfenidone
Locations: Graz, Austria
Innsbruck, Austria
Salzburg, Austria
Bruxelles, Belgium
Leuven, Belgium
... and 65 other locations.
Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis
Status: Completed
Last Changed: May 26, 2020
First Received: Jan 26, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): SAR156597, placebo
Locations: Investigational Site Number 840003, Phoenix, Arizona, United States
Investigational Site Number 840020, Jacksonville, Florida, United States
Investigational Site Number 840022, Loxahatchee Groves, Florida, United States
Investigational Site Number 840017, Atlanta, Georgia, United States
Investigational Site Number 840008, Decatur, Georgia, United States
... and 97 other locations.